Effects of Long-Term Storage at -80 °C on the Human Plasma Metabolome.

biomarker long-term stability mass spectrometry metabolomics plasma storage

Journal

Metabolites
ISSN: 2218-1989
Titre abrégé: Metabolites
Pays: Switzerland
ID NLM: 101578790

Informations de publication

Date de publication:
17 May 2019
Historique:
received: 20 03 2019
revised: 26 04 2019
accepted: 14 05 2019
entrez: 22 5 2019
pubmed: 22 5 2019
medline: 22 5 2019
Statut: epublish

Résumé

High-quality biological samples are required for the favorable outcome of research studies, and valid data sets are crucial for successful biomarker identification. Prolonged storage of biospecimens may have an artificial effect on compound levels. In order to investigate the potential effects of long-term storage on the metabolome, human ethylenediaminetetraacetic acid (EDTA) plasma samples stored for up to 16 years were analyzed by gas and liquid chromatography-tandem mass spectrometry-based metabolomics. Only 2% of 231 tested plasma metabolites were altered in the first seven years of storage. However, upon longer storage periods of up to 16 years and more time differences of few years significantly affected up to 26% of the investigated metabolites when analyzed within subject age groups. Ontology classes that were most affected included complex lipids, fatty acids, energy metabolism molecules, and amino acids. In conclusion, the human plasma metabolome is adequately stable to long-term storage at -80 °C for up to seven years but significant changes occur upon longer storage. However, other biospecimens may display different sensitivities to long-term storage. Therefore, in retrospective studies on EDTA plasma samples, analysis is best performed within the first seven years of storage.

Identifiants

pubmed: 31108909
pii: metabo9050099
doi: 10.3390/metabo9050099
pmc: PMC6572224
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1837-40
pubmed: 16030126
Arterioscler Thromb Vasc Biol. 2005 Nov;25(11):2368-75
pubmed: 16141402
Crit Rev Biochem Mol Biol. 1991;26(1):1-52
pubmed: 1678690
Anal Chem. 2006 Jul 1;78(13):4307-18
pubmed: 16808437
Expert Rev Proteomics. 2006 Aug;3(4):409-26
pubmed: 16901200
Toxicol Lett. 2007 Jul 30;172(1-2):21-8
pubmed: 17614222
Cancer Treat Res. 2007;138:83-109
pubmed: 18080659
PLoS One. 2009 Nov 19;4(11):e7905
pubmed: 19936240
Metabolomics. 2009 Dec;5(4):507-516
pubmed: 20046864
Anal Biochem. 2010 Nov 15;406(2):105-12
pubmed: 20655863
J Natl Cancer Inst. 2010 Oct 6;102(19):1462-7
pubmed: 20705936
J Biomed Biotechnol. 2011;2011:790132
pubmed: 21274272
J Biomol NMR. 2011 Apr;49(3-4):231-43
pubmed: 21380509
Nat Med. 2011 Apr;17(4):448-53
pubmed: 21423183
Nat Protoc. 2011 Jun 30;6(7):1060-83
pubmed: 21720319
J Biomol NMR. 2011 Dec;51(4):457-65
pubmed: 21964699
Clin Chem. 2012 Jan;58(1):139-47
pubmed: 22110018
Clin Chem. 2012 Feb;58(2):402-10
pubmed: 22194632
Clin Chim Acta. 2012 Apr 11;413(7-8):779-86
pubmed: 22285774
PLoS One. 2012;7(6):e38290
pubmed: 22701622
Clin Chem Lab Med. 2013 Jan;51(1):229-41
pubmed: 23072858
J Clin Biochem Nutr. 2013 Jan;52(1):9-16
pubmed: 23341691
Environ Health Perspect. 2013 Apr;121(4):480-7
pubmed: 23384616
Clin Chem. 2013 May;59(5):833-45
pubmed: 23386698
Anal Chem. 2013 Mar 5;85(5):2606-10
pubmed: 23387999
J Pharm Biomed Anal. 2014 Jan;87:1-11
pubmed: 24091079
Clin Chem. 2014 Feb;60(2):399-412
pubmed: 24305685
Clin Biochem. 2014 Mar;47(4-5):258-66
pubmed: 24424103
PLoS One. 2014 Feb 24;9(2):e89728
pubmed: 24586991
Lancet Diabetes Endocrinol. 2014 Jan;2(1):65-75
pubmed: 24622670
J Endocrinol. 2014 Jun;221(3):R75-85
pubmed: 24868111
Biopreserv Biobank. 2014 Jun;12(3):165-75
pubmed: 24918763
PLoS Genet. 2014 Dec 11;10(12):e1004801
pubmed: 25502724
J Pharm Biomed Anal. 2015 Mar 25;107:63-74
pubmed: 25569286
Anal Bioanal Chem. 2015 Jul;407(17):4879-92
pubmed: 25736245
Electrophoresis. 2015 Sep;36(18):2148-2155
pubmed: 25820922
PLoS One. 2015 Mar 30;10(3):e0121495
pubmed: 25823017
Clin Chem. 2015 Jul;61(7):914-34
pubmed: 25979952
J Proteome Res. 2015 Jul 2;14(7):2758-68
pubmed: 26036795
Oncotarget. 2016 Jan 12;7(2):1421-38
pubmed: 26623558
J Lipid Res. 1989 Mar;30(3):305-15
pubmed: 2723538
Environ Int. 2017 Oct;107:8-15
pubmed: 28648904
J Proteome Res. 2018 Jan 5;17(1):203-211
pubmed: 29064256
Metabolites. 2018 Jan 13;8(1):null
pubmed: 29342854
J Biol Chem. 1975 Dec 25;250(24):9342-7
pubmed: 394
Science. 1980 Nov 28;210(4473):978-84
pubmed: 6254151
Biochim Biophys Acta. 1996 Jan 19;1299(2):223-34
pubmed: 8555268

Auteurs

Antje Wagner-Golbs (A)

Metanomics Health GmbH, Tegeler Weg 33, 10589 Berlin, Germany. antje.wagner-golbs@metanomics-health.de.

Sebastian Neuber (S)

Biocrates Life Sciences AG, Eduard-Bodem-Gasse 8, 6020 Innsbruck, Austria. sebastian.neuber@biocrates.com.

Beate Kamlage (B)

Metanomics Health GmbH, Tegeler Weg 33, 10589 Berlin, Germany. beate.kamlage@metanomics-health.de.

Nicole Christiansen (N)

Metanomics Health GmbH, Tegeler Weg 33, 10589 Berlin, Germany. nicole.christiansen@metanomics-health.de.

Bianca Bethan (B)

Metanomics Health GmbH, Tegeler Weg 33, 10589 Berlin, Germany. bianca.bethan@metanomics-health.de.

Ulrike Rennefahrt (U)

Metanomics Health GmbH, Tegeler Weg 33, 10589 Berlin, Germany. ulrike.rennefahrt@metanomics-health.de.

Philipp Schatz (P)

Metanomics Health GmbH, Tegeler Weg 33, 10589 Berlin, Germany. philipp.schatz@astrazeneca.com.

Lars Lind (L)

Department of Medical Sciences, Cardiovascular Epidemiology, Uppsala University, Dag Hammarskjöldsv 10 B, Uppsala Science Park, 75237 Uppsala, Sweden. lars.lind@medsci.uu.se.

Classifications MeSH